top of page
Search

Ambu: Investing in a Leader in Disposable Endoscopy

7 hours ago
52 min read

Ambu is a Danish medical technology company specializing in single-use endoscopes and other medical devices used by hospitals worldwide. The company is the global market leader in single-use endoscopy, providing small cameras that allow doctors to examine areas inside the body, including the lungs, bladder, throat, and digestive system. Ambu also supplies equipment used for breathing assistance, anesthesia, and patient monitoring. With a growing range of products, new generations of endoscopes under development, and an increasing focus on software and artificial intelligence, Ambu aims to benefit as more hospitals replace reusable endoscopes with single-use alternatives. The question remains: Does this Danish medical technology company deserve a spot in your portfolio?


This is not financial advice. I am not a financial advisor, and I publish these analyses to document my own research and share my thoughts with readers and followers. If you are considering investing in any of the companies or ideas discussed, you should always do your own research and, if necessary, consult a qualified financial professional. All investing involves risk, and you may lose some or all of the money you invest.


For full disclosure, I do not own shares in Ambu at the time of writing this analysis. I publicly share my investment portfolio, including all of my current holdings and changes I make over time. If you are interested in seeing what I currently invest in and learning how you can follow or copy my portfolio, you can read more here.




The Business


Ambu is a Danish medical technology company that develops, manufactures, and sells medical devices used by hospitals and healthcare professionals worldwide. Founded in 1937 and headquartered in Ballerup, Denmark, the company has a long history of developing products that improve patient safety and make medical procedures easier and more efficient. Today, Ambu employs approximately 5.400 people, sells its products in more than 60 markets, and estimates that its solutions help more than 100 million patients every year.


Ambu is particularly known for pioneering single-use endoscopy, a technology that allows doctors to examine and treat patients using disposable endoscopes rather than traditional reusable instruments. The company has established itself as the global market leader in single-use endoscopy, with a market share exceeding 60%, while maintaining an established business in anesthesia and patient monitoring.


To understand Ambu's business, it is important to understand what an endoscope actually does. An endoscope is a medical instrument that allows doctors to look inside the human body without performing major surgery. It typically consists of a long, thin, flexible tube with a miniature camera and lighting at the tip. The instrument is inserted through a natural opening, such as the mouth, nose, or urinary tract, allowing doctors to examine internal organs, identify abnormalities, collect tissue samples, and sometimes perform treatments.


Endoscopy is an important part of modern healthcare. More than 150 million endoscopy procedures are performed globally every year, including more than 100 million in the United States, Europe, and Japan. These procedures are used to diagnose conditions such as lung disease, cancer, gastrointestinal disorders, and urinary tract problems. As populations age and healthcare systems increasingly focus on early diagnosis and minimally invasive treatments, demand for endoscopy procedures is expected to grow.


Traditionally, hospitals have performed these procedures using reusable endoscopes. These instruments are manufactured by companies such as Olympus, Fujifilm, and Karl Storz and can be used repeatedly over several years. However, after every procedure, they must undergo extensive cleaning, disinfection, inspection, and preparation before they can be used on another patient.


This process requires specialized equipment, trained personnel, chemicals, storage facilities, and careful documentation. Reusable endoscopes can also be expensive to purchase and repair, particularly when their delicate cameras or internal components become damaged. If cleaning procedures are not performed correctly, there is also a risk of transferring infections between patients.


Ambu has built much of its business around offering an alternative. Its single-use endoscopes are supplied sterile and are designed to be used for one procedure before being discarded. This eliminates the need to clean and reprocess the instrument between patients, reduces the risk of infections associated with contaminated reusable endoscopes, and allows hospitals to have equipment available whenever it is needed.


The economic benefits depend on the clinical application and how frequently a hospital performs procedures. Hospitals with large procedure volumes may achieve attractive economics from reusable endoscopes because their initial purchase costs can be spread across many procedures. However, hospitals with lower procedure volumes, expensive cleaning requirements, or frequent repair costs may find single-use solutions more economical.


Single-use endoscopes can also improve operational flexibility. Instead of depending on the availability of a cleaned reusable instrument, healthcare professionals can open a sterile device when needed. This can be particularly valuable in intensive care units, emergency departments, and other environments where procedures cannot always be scheduled in advance.


Ambu operates through two main business areas: Endoscopy Solutions and Anesthesia and Patient Monitoring.


Endoscopy Solutions is Ambu's largest and most important business area, accounting for approximately two-thirds of group revenue. This division develops and sells single-use endoscopes and associated visualization equipment used across four major clinical specialties: respiratory endoscopy, urology, ear, nose and throat procedures, and gastrointestinal endoscopy.


Respiratory endoscopy, particularly bronchoscopy, is Ambu's most established single-use endoscopy market. Bronchoscopy involves inserting a thin camera into a patient's airways to examine the lungs, investigate infections, collect samples, or assist with certain treatments. The procedure is commonly performed in intensive care units, operating rooms, and respiratory departments.


Ambu introduced its first single-use flexible bronchoscope in 2009, making it a pioneer in the market. Its aScope portfolio has since evolved through several product generations, offering improved image quality, maneuverability, and functionality. Because respiratory endoscopy was one of the earliest clinical areas to adopt disposable scopes, Ambu has accumulated considerable experience in understanding how hospitals use these devices and what clinicians require from them.


Urology represents another important market. Urologists use endoscopes to examine the urinary tract, diagnose conditions, and perform procedures involving the bladder, ureters, and kidneys. Ambu offers single-use cystoscopes and ureteroscopes, including products within its aScope portfolio.


These devices can be particularly attractive because reusable urology scopes are delicate instruments that may require expensive repairs. Single-use alternatives eliminate reprocessing and repair requirements for the scope itself while allowing hospitals to use a new sterile instrument for every procedure.


Ear, nose and throat, commonly referred to as ENT, is another area where Ambu has expanded its portfolio. ENT specialists use flexible endoscopes to examine the nasal passages, throat, larynx, and surrounding structures. These procedures are performed in hospitals and outpatient clinics, often to investigate breathing difficulties, swallowing disorders, voice problems, and suspected abnormalities.


Ambu's single-use ENT endoscopes allow clinicians to perform examinations without needing to send instruments for cleaning after every patient. This can be particularly useful in busy outpatient environments where multiple patients are examined throughout the day and equipment availability affects how efficiently clinicians can work.


Gastrointestinal endoscopy, or GI, represents a particularly significant long-term growth opportunity. Gastroenterologists use endoscopes to examine the digestive system, including the esophagus, stomach, small intestine, and colon. These procedures are essential for diagnosing gastrointestinal diseases, investigating symptoms, screening for cancer, and performing treatments.


The gastrointestinal endoscopy market is substantially larger than several of Ambu's other endoscopy markets, but it is also more challenging for single-use technology to penetrate. Reusable gastrointestinal endoscopes are well established, and hospitals performing large numbers of procedures can spread their equipment costs across substantial volumes. In addition, gastrointestinal procedures often require sophisticated imaging, precise maneuverability, and specialized therapeutic capabilities.


Ambu has been developing single-use solutions for gastrointestinal procedures, including gastroscopy and duodenoscopy. The opportunity is significant because even relatively modest adoption of disposable technology within this large market could create substantial additional demand. However, adoption depends on whether Ambu can deliver clinical performance and economics that make its products attractive compared with established reusable alternatives.


Across these four specialties, Ambu offers what it describes as the industry's broadest portfolio of single-use endoscopes. This is important because large hospitals and healthcare systems often operate several endoscopy departments with different equipment requirements. Rather than supplying a single disposable instrument for one specialized procedure, Ambu can offer solutions covering multiple clinical areas.


Ambu is also developing its business beyond the endoscope itself. The company increasingly positions itself as a provider of integrated endoscopy solutions, including visualization systems, software, and technologies that support the entire clinical workflow.


Its aBox visualization systems are an important part of this strategy. These systems connect to compatible Ambu endoscopes and display the images captured during procedures. Rather than requiring hospitals to purchase a separate visualization setup for every clinical specialty, Ambu is working toward a more standardized technology platform that can support multiple endoscope types.


The company's proprietary EndoIntelligence technology platform is intended to support this approach by providing common imaging and visualization capabilities across its endoscopy portfolio. Standardizing technology across different products can make it easier to develop new endoscopes, improve performance, and introduce additional features without having to develop entirely separate systems for every clinical application.


This approach also changes Ambu's relationship with customers. Instead of simply selling disposable endoscopes, the company can become involved in how hospitals organize their endoscopy equipment, standardize clinical workflows, and manage procedures across departments.


The business model generates recurring revenue because hospitals must purchase a new single-use endoscope for every procedure. Unlike a manufacturer of reusable endoscopes, which may sell an instrument that remains in service for several years, Ambu generates additional product sales whenever customers perform more procedures using its devices.


This creates a direct relationship between procedure volumes, customer adoption, and revenue. Once a hospital begins using Ambu's single-use endoscopes regularly, continued clinical activity generates repeat orders. Revenue can grow both as existing customers perform more procedures and as additional hospitals adopt the technology.


However, the recurring nature of the business does not mean that demand is guaranteed. Hospitals can evaluate competing single-use devices, renegotiate purchasing agreements, or decide to continue using reusable instruments. Ambu must therefore maintain attractive clinical performance, reliable supply, and competitive pricing to retain and expand its customer relationships.


Anesthesia and Patient Monitoring is Ambu's second business area, accounting for approximately one-third of group revenue. This division represents the company's more established medical device activities and provides products used in ventilation, resuscitation, anesthesia, and patient monitoring.


One of Ambu's best-known inventions is the Ambu bag, a manual resuscitator developed in the 1950s. This device allows healthcare professionals to deliver air or oxygen to patients who are unable to breathe adequately on their own. It is widely used in ambulances, emergency departments, operating rooms, and intensive care units.


Ambu continues to manufacture resuscitation and ventilation equipment, including products used to support breathing during medical emergencies and surgical procedures. Many of these products are essential hospital consumables that must be readily available when needed.


The patient monitoring business includes electrodes and other products used to measure physiological signals. For example, electrocardiogram electrodes are attached to a patient's skin to record the electrical activity of the heart, while other electrodes can be used to monitor brain activity or support neurological examinations.


Although these products are generally less technologically differentiated than Ambu's advanced endoscopy solutions, they benefit from recurring demand because hospitals continuously use and replace medical consumables. They also have established applications in healthcare systems worldwide.


Anesthesia and Patient Monitoring therefore provides Ambu with a relatively mature business alongside its faster-growing endoscopy activities. Its products serve essential medical needs, and demand is supported by ongoing hospital activity rather than depending primarily on the adoption of an emerging technology.


Ambu's manufacturing and product development capabilities are important parts of its business model. The company operates four manufacturing facilities located in Malaysia, China, Mexico, and the United States, supported by three major research and development centers in Denmark, Germany, and Malaysia.


This global structure allows Ambu to combine product development with manufacturing capabilities located closer to important suppliers and customers. The United States is Ambu's largest market, making the expansion of its Mexican manufacturing facility particularly important for improving regional supply, reducing logistical complexity, and limiting exposure to certain tariffs.


Manufacturing single-use endoscopes at scale requires a different approach from producing traditional reusable medical equipment. Because every procedure requires a new instrument, Ambu must manufacture large quantities of devices while maintaining strict medical quality standards and controlling production costs.


The company therefore places considerable emphasis on standardized manufacturing processes, efficient material usage, automation, and modular production facilities that can expand as demand increases. Improving manufacturing efficiency is important because reducing the cost of each endoscope can support profitability while making single-use technology more attractive to hospitals.


Ambu also maintains considerable control over its value chain. It develops its products, manages important manufacturing activities, operates its own commercial organization, and maintains direct relationships with hospitals and healthcare professionals. External suppliers provide raw materials, electronics, plastics, and other components, but Ambu retains responsibility for product design, manufacturing quality, regulatory compliance, and commercialization.


Research and development is another important investment area. Ambu reinvests approximately 10% of its endoscopy revenue into R&D, supporting the development of new products, improvements to existing devices, and technologies that can be shared across its portfolio.


Product development is closely connected to clinical practice. Ambu works with physicians, nurses, hospital administrators, and other healthcare professionals to understand the challenges they encounter during procedures. These insights help the company improve aspects such as image quality, instrument flexibility, ergonomics, ease of use, and workflow efficiency.


This customer-centric approach is particularly important because purchasing decisions in healthcare involve several stakeholders. Clinicians may prioritize image quality, maneuverability, and patient safety, while hospital administrators and purchasing departments focus on costs, operational efficiency, reliability, and standardization.


Ambu has therefore expanded its commercial approach beyond individual physicians to include hospital management and larger healthcare systems. By demonstrating how its solutions can improve clinical workflows and potentially reduce the total cost of procedures, Ambu aims to establish broader relationships that extend across multiple hospital departments.


The company has also made sustainability an increasingly important part of its product development and operations. Single-use medical devices create environmental challenges because they generate waste after every procedure. Ambu is responding by introducing bioplastics in endoscope handles, exploring recycling initiatives, improving material efficiency, and reducing emissions associated with manufacturing and transportation.


Ambu's competitive moat is primarily built on its leadership in single-use endoscopy, established customer relationships, manufacturing scale, proprietary technology, and integration into hospital workflows. As the pioneer of single-use endoscopy, Ambu has developed specialized expertise, a broad product portfolio, and a global commercial presence that would be difficult for smaller competitors to replicate quickly.


One of Ambu's most important strengths is its leading market position. The company introduced its first single-use flexible bronchoscope in 2009 and has since established a global market share exceeding 60% in single-use endoscopy. This early entry has allowed Ambu to build extensive clinical experience, develop relationships with healthcare professionals, and establish a reputation for reliable medical devices. Its leadership also provides an important advantage as more hospitals consider replacing reusable endoscopes with single-use alternatives.


Customer relationships are another important part of Ambu's moat. The company works closely with clinicians, hospital administrators, and healthcare systems to understand their requirements and develop solutions that improve clinical performance and operational efficiency. According to Ambu's customer research, the company has approximately 80% brand awareness among surveyed customers in the United States and Europe, ranking ahead of other single-use endoscopy providers. This established reputation can make it easier to introduce new products and expand relationships with existing customers.


These relationships can also create switching costs. When hospitals adopt Ambu's endoscopes, employees become familiar with the instruments, visualization systems, and associated procedures. As hospitals increasingly standardize equipment across departments and integrate Ambu's technology into clinical workflows, changing suppliers may require new equipment, additional training, and adjustments to established routines. However, switching costs are not absolute, as hospitals can evaluate competing products and purchasing decisions remain sensitive to clinical performance and economics.


Ambu's manufacturing scale provides another advantage. The company operates four manufacturing facilities in Malaysia, China, Mexico, and the United States, allowing it to produce large quantities of medical devices while maintaining consistent quality and reliable supply. Its leading position in single-use endoscopy provides opportunities to spread development and manufacturing costs across substantial production volumes, potentially allowing Ambu to achieve lower unit costs than smaller competitors. The continued expansion of its manufacturing capabilities, particularly in Mexico, also strengthens supply chain resilience and brings production closer to important markets.


Technology and innovation further reinforce Ambu's position. The company operates three major R&D centers and reinvests approximately 10% of endoscopy revenue into research and development. Its proprietary EndoIntelligence platform supports the development of connected endoscopy solutions across multiple clinical specialties, while its broad portfolio allows technological improvements to be introduced across different product categories. This combination of specialized expertise, intellectual property, and continuous product development helps Ambu maintain its position in a market where clinical performance and usability are important purchasing considerations.


Ambu's established anesthesia and patient monitoring business provides an additional foundation. Products such as resuscitators, ventilation equipment, and monitoring electrodes have been used by healthcare professionals for decades, giving the company longstanding relationships with hospitals and distributors. Although these products generally face greater price competition and have a less substantial moat than single-use endoscopy, they contribute recurring revenue and strengthen Ambu's reputation as a reliable medical technology supplier.


Sustainability is becoming another consideration in Ambu's relationships with hospitals. Single-use medical devices generate waste, which can create challenges as healthcare systems seek to reduce their environmental impact. Ambu is addressing this through initiatives such as bioplastic endoscope handles, recycling programs, and more efficient manufacturing processes. While these initiatives are unlikely to create a substantial moat independently, they may help Ambu differentiate its products and support hospitals in meeting their sustainability objectives.


Overall, Ambu's competitive position benefits from the combination of market leadership, customer relationships, manufacturing scale, and technological expertise. Its most important advantage is that these strengths reinforce one another. A large customer base supports recurring demand and manufacturing efficiency, while close collaboration with clinicians helps Ambu develop products that meet changing healthcare requirements. As the single-use endoscopy market expands, this established infrastructure could allow Ambu to grow more efficiently than smaller competitors. However, its moat will ultimately depend on maintaining clinical performance, competitive pricing, and reliable supply as established medical technology companies increase their presence in the market.


Management


Britt Meelby Jensen serves as the CEO of Ambu, a role she assumed in May 2022 after previously serving on the company's Board of Directors since 2019. Britt Meelby Jensen has more than two decades of experience in the global healthcare industry, including senior leadership positions at Novo Nordisk, Dako, Zealand Pharma, and Atos Medical. Throughout her career, she has developed extensive experience in commercial strategy, organizational development, international expansion, and improving the performance of healthcare companies.


This experience is particularly relevant to Ambu because the company is transitioning from being primarily a medical device manufacturer toward becoming a global provider of integrated single-use endoscopy solutions. The transition requires not only technological innovation but also stronger commercial execution, efficient manufacturing, closer relationships with hospitals, and the ability to scale operations while improving profitability.


Britt Meelby Jensen began her professional career at McKinsey & Company, where she worked with strategy and organizational development before joining Novo Nordisk. During more than a decade at Novo Nordisk, she held several leadership positions and eventually became Corporate Vice President of Global Marketing, Market Access, and Commercial Excellence.


Her responsibilities included developing commercial strategies, improving market access, and strengthening the company's ability to bring pharmaceutical products to patients across international markets. This provided her with extensive experience operating in a highly regulated healthcare industry where commercial success depends on understanding physicians, healthcare systems, reimbursement structures, and other stakeholders.


In 2013, Britt Meelby Jensen became CEO of Dako, a Danish cancer diagnostics company that had become part of Agilent Technologies. Dako develops diagnostic technologies used by hospitals and laboratories, particularly in cancer diagnosis. Her responsibilities included strengthening commercial execution and improving organizational performance within a specialized healthcare technology business.


She subsequently became President and CEO of Zealand Pharma in 2015. Zealand Pharma is a Danish biotechnology company focused on developing peptide-based medicines, including treatments for metabolic and gastrointestinal diseases.


During her tenure, Britt Meelby Jensen oversaw the advancement of Zealand Pharma's development pipeline and helped strengthen the company's international profile. One important milestone was Zealand Pharma's listing on Nasdaq in the United States in 2017, which expanded its access to international investors and increased its visibility in the American biotechnology market.


Her experience at Zealand Pharma provided valuable insight into managing a publicly listed healthcare company, allocating capital to research and development, communicating with investors, and balancing long-term product development with financial discipline.


In 2019, Britt Meelby Jensen became CEO of Atos Medical, a Swedish medical technology company specializing in products for people who have undergone a laryngectomy, a surgical procedure involving removal of the voice box, often as part of cancer treatment.


Atos Medical develops and sells specialized medical devices that help patients breathe, speak, and manage their condition following surgery. Its products include voice prostheses and other devices that patients frequently depend on for the rest of their lives.


This business has similarities to Ambu because both companies operate in specialized medical technology markets where clinical performance, patient outcomes, healthcare professional relationships, and recurring product demand are important.


At Atos Medical, Britt Meelby Jensen focused on strengthening the company's commercial capabilities, expanding its international presence, and improving operational performance. During her tenure, Atos Medical continued developing its position in the global laryngectomy market and ultimately attracted the attention of Coloplast.


In 2021, Coloplast announced the acquisition of Atos Medical for approximately EUR 2,16 billion, with the transaction completed in early 2022. Britt Meelby Jensen's involvement in developing Atos Medical and leading the company through its sale provided another example of her experience creating value in specialized healthcare businesses.


Britt Meelby Jensen joined Ambu as CEO in May 2022 at a challenging point in the company's development. Ambu had experienced a period of rapid expansion, particularly during the COVID-19 pandemic, when demand for single-use bronchoscopy increased significantly. However, the company subsequently faced slower growth, profitability pressure, and challenges related to its commercial organization and operational execution.


Ambu had invested heavily in expanding its single-use endoscopy business, but the company needed to demonstrate that these investments could translate into sustainable growth and improved profitability. The Board therefore appointed Britt Meelby Jensen to strengthen execution, establish clearer strategic priorities, and improve the company's financial performance.


One of her most important early initiatives was the introduction of Ambu's ZOOM IN strategy, which established a more focused approach to developing the company's single-use endoscopy business.


The strategy emphasized strengthening Ambu's leadership in single-use endoscopy, improving commercial execution, prioritizing product development, and creating a more efficient organization. Rather than pursuing growth without sufficient consideration of profitability, Ambu increasingly focused on balancing revenue expansion with operational discipline and financial returns.


Under Britt Meelby Jensen, Ambu has worked to strengthen its commercial organization and become more closely connected to the needs of hospitals and healthcare systems. The company has expanded its engagement beyond individual clinicians to include hospital administrators and purchasing decision-makers, reflecting the importance of demonstrating both clinical and economic benefits.


This approach is particularly relevant because Ambu's long-term growth depends on convincing hospitals to adopt single-use endoscopes instead of established reusable alternatives. Even when clinicians prefer a disposable product, hospitals must consider purchasing costs, workflow requirements, and the economics of changing equipment.


Britt Meelby Jensen's experience in commercial strategy and market access is therefore valuable. Ambu needs to communicate not only the clinical benefits of its products but also how they can improve efficiency, simplify hospital operations, and potentially reduce the total cost of procedures.


Another important priority has been strengthening Ambu's manufacturing capabilities and improving operational efficiency. The company has continued expanding its global manufacturing footprint, including the ramp-up of its facility in Mexico and further development of its production operations in Malaysia.


These investments are intended to support growing demand while improving supply chain resilience and manufacturing efficiency. Because single-use endoscopy requires producing a new instrument for every procedure, the ability to manufacture high-quality devices at competitive costs is essential to Ambu's long-term profitability.


Britt Meelby Jensen has also emphasized simplifying and standardizing business processes across the organization. Ambu has been improving its data infrastructure, strengthening reporting capabilities, and preparing upgrades to its core business systems to support more efficient decision-making and greater automation.


These initiatives may be less visible than new product launches, but they are important as Ambu grows. A company operating manufacturing facilities and commercial organizations across multiple continents needs reliable processes, consistent data, and efficient coordination to maintain profitability and operational control.


Innovation remains central to Ambu's strategy under Britt Meelby Jensen. The company continues investing heavily in research and development, expanding its portfolio of single-use endoscopes and developing technologies that support more integrated endoscopy solutions.


An important strategic development has been Ambu's increasing emphasis on becoming a full-solution partner for hospitals rather than simply supplying disposable endoscopes. The company's EndoIntelligence platform supports this direction by connecting endoscopes, visualization systems, and digital capabilities across different clinical specialties.


The acquisition of TIMS Medical in September 2026 represents another step in this strategy. By adding capabilities in medical video connectivity, recording, and documentation, Ambu is expanding its presence in the broader endoscopy workflow.


This could strengthen customer relationships and create additional opportunities to differentiate Ambu's solutions from competing single-use products. It also demonstrates that Britt Meelby Jensen's strategy increasingly involves combining organic product development with selective acquisitions that support Ambu's existing technology platform.


Financial performance has improved during her tenure. In the 2025/26 financial year, Ambu reported revenue of approximately DKK 6,47 billion, organic revenue growth of 10,1%, and an EBIT margin before special items of 13,2%. Endoscopy Solutions continued to drive growth, supported by increasing adoption of single-use products across multiple specialties.


These results indicate that Ambu has made progress toward combining growth with improving profitability, although the company's longer-term financial performance will depend on continued market adoption, manufacturing efficiency, and its ability to maintain attractive margins as competition increases.


Britt Meelby Jensen is also recognized for her leadership approach. She has emphasized clear strategic priorities, accountability, collaboration, and the importance of building an organization where employees understand how their responsibilities contribute to the company's overall objectives.


Her leadership has received recognition outside Ambu. In 2024, she was named Leader of the Year in Denmark, reflecting her reputation within the Danish business community and her experience leading organizations through periods of strategic and operational change.


In addition to her executive responsibilities, Britt Meelby Jensen serves as Vice Chair of Novo Holdings and holds other board positions, including Novo Nordisk and the Confederation of Danish Industry. These positions reflect her extensive experience and relationships within the Danish healthcare and business communities.


Britt Meelby Jensen holds a Master's degree in International Marketing from Copenhagen Business School and an MBA from Solvay Business School in Brussels. According to Ambu's 2025/26 annual report, she owns 149.736 Ambu B shares.


Britt Meelby Jensen's background is particularly well suited to Ambu's current stage of development. Unlike a CEO whose experience is primarily concentrated in scientific research or engineering, she has built her career around commercial strategy, organizational leadership, and improving the performance of healthcare businesses.


This is relevant because Ambu already possesses substantial technological expertise and a leading position in single-use endoscopy. The company's most important challenges increasingly involve converting that leadership into sustainable revenue growth, expanding adoption across hospitals, improving manufacturing economics, and strengthening profitability.


Her previous experience at Atos Medical is especially relevant because it involved developing a specialized medical technology company with recurring product demand, close relationships with healthcare professionals, and opportunities for international expansion.


At the same time, Ambu operates in a highly competitive market, and the company's future performance cannot be attributed solely to management. Continued growth will depend on technological developments, hospital purchasing decisions, the economics of single-use endoscopy, and the competitive responses of established medical device manufacturers.


Overall, Britt Meelby Jensen brings a combination of commercial expertise, international healthcare experience, and a demonstrated ability to lead organizations through strategic transitions. Since joining Ambu, she has established clearer priorities around profitable growth, commercial execution, manufacturing efficiency, and integrated endoscopy solutions.


The key test over the coming years will be whether Britt Meelby Jensen can continue translating Ambu's leading position in single-use endoscopy into sustained growth, stronger profitability, and attractive returns for shareholders while defending the company's moat as competition increases.


The Numbers


The first number we will look into is the return on invested capital, also known as ROIC. We want to see a 10-year history, with all numbers exceeding 10% in each year. Ambu does not meet this requirement, as ROIC has exceeded 10% in only four of the past ten years. After reaching 18,4% in 2017, ROIC declined considerably and bottomed at just 1,8% in 2022. Since then, profitability has gradually recovered, with ROIC reaching 10,1% in fiscal year 2026.


Ambu's ROIC development reflects a company that transitioned from a relatively focused and highly profitable medical device manufacturer into a much larger business investing heavily in the global expansion of single-use endoscopy. The decline was driven by a combination of significant investments, rising operating expenses, slower-than-expected growth in certain markets, and pressure on profitability. More recently, the company has started benefiting from stronger commercial execution, improving margins, and better utilization of its manufacturing capacity.


Between 2017 and 2019, Ambu generated consistently attractive returns on invested capital, with ROIC ranging from 11,7% to 18,4%. During this period, the company benefited from strong growth in single-use endoscopy, particularly respiratory endoscopy, where it had established an early leadership position. Its business was also smaller and less complex, allowing Ambu to generate attractive earnings without requiring the same level of investment in manufacturing facilities, product development, and international commercial infrastructure that would characterize the following years.


Ambu's early leadership in single-use bronchoscopy was particularly important. The company had pioneered the technology and faced relatively limited direct competition in a market where hospitals were beginning to recognize the benefits of disposable endoscopes. As sales increased, Ambu could spread existing development, manufacturing, and organizational costs across a growing number of devices. This supported profitability and helped the company generate attractive returns relative to the capital invested in the business.


However, the situation began changing as Ambu pursued a much more ambitious expansion strategy. The company saw an opportunity to establish single-use endoscopy across several additional clinical specialties, including urology, ENT, and gastrointestinal endoscopy. To capture this opportunity, Ambu invested heavily in research and development, manufacturing capacity, its global sales organization, and the infrastructure needed to support a much larger business.


These investments were intended to position Ambu for substantial long-term growth, but they also increased the amount of capital tied up in the business. New manufacturing facilities, production equipment, inventories, and other investments increased the capital required to operate the company before the associated revenue and profits had fully materialized.


This is particularly important when evaluating ROIC because the metric measures how efficiently a company generates operating profits from the capital invested in its business. When invested capital increases faster than operating earnings, ROIC declines even if the investments are intended to create substantial value over the longer term.


The decline became particularly pronounced between 2020 and 2022, when ROIC fell from 9,5% to just 1,8%. Ambu was expanding its operations and commercial organization while facing significant uncertainty surrounding the COVID-19 pandemic and the subsequent normalization of healthcare activity.


The pandemic initially created additional demand for single-use bronchoscopes because hospitals were particularly concerned about infection prevention. However, the broader disruption to healthcare systems also affected elective procedures, hospital purchasing decisions, and the introduction of new medical technologies. As pandemic-related demand normalized, Ambu faced a more challenging environment while continuing to carry the costs of its expanded organization.


At the same time, the adoption of single-use endoscopy in newer clinical specialties developed more slowly than Ambu had anticipated. Gastrointestinal endoscopy was particularly challenging because hospitals already had substantial investments in reusable equipment, and single-use alternatives needed to demonstrate comparable clinical performance and attractive economics.


Ambu had invested in developing products and preparing its organization for a much larger market opportunity, but the expected revenue did not arrive quickly enough to support the expanded cost structure. The company therefore experienced pressure on operating margins while its invested capital remained elevated.


This combination explains much of the deterioration in ROIC. Ambu was investing for future growth, but the earnings generated from those investments were insufficient to maintain its historically attractive returns. The company had become more capital-intensive and operationally complex without achieving the expected improvement in profitability.


The appointment of Britt Meelby Jensen as CEO in 2022 marked an important turning point. She introduced a more focused strategic approach through Ambu's ZOOM IN strategy, emphasizing stronger commercial execution, clearer priorities, operational efficiency, and a better balance between growth and profitability.


Rather than continuing to expand the organization at the same pace, Ambu began focusing more closely on improving the performance of its existing business and ensuring that investments supported sustainable, profitable growth. This included strengthening customer relationships, improving manufacturing efficiency, simplifying operations, and concentrating resources on the most attractive opportunities within single-use endoscopy.


The recovery in ROIC since 2022 has been substantial. It increased from 1,8% in 2022 to 4,0% in 2023, 8,5% in 2024, 9,9% in 2025, and 10,1% in 2026. This improvement suggests that Ambu has become more effective at generating operating profits from its invested capital, although returns remain considerably below the levels achieved before the company's major expansion.


Improving profitability has been an important driver of this recovery. Ambu has strengthened commercial execution, increased sales volumes, and improved operational discipline. Higher production volumes also allow the company to utilize its manufacturing facilities more efficiently and spread fixed production costs across more devices.


The growth of Endoscopy Solutions has been particularly important because this business represents Ambu's largest long-term growth opportunity. As more hospitals adopt single-use endoscopes and existing customers increase their procedure volumes, Ambu can generate additional revenue from products and manufacturing capabilities that have already been developed.


However, it would be misleading to suggest that Ambu has completely finished investing in manufacturing capacity. The company has continued expanding its production footprint, including the ramp-up of its Mexican facility and improvements to its operations in Malaysia. It also continues investing in research and development, digital technology, and its commercial organization.


The difference is that Ambu is now placing greater emphasis on scaling these investments efficiently and ensuring that revenue and earnings grow faster than the capital required to support them. This is important because a growing business can improve ROIC even while continuing to invest, provided the additional operating profits exceed the proportional increase in invested capital.


Looking ahead, there are several reasons to believe that Ambu could continue improving its ROIC. The company has already established a global manufacturing platform, developed an extensive portfolio of single-use endoscopes, and built commercial relationships across its most important healthcare markets. These investments provide a foundation for future growth without necessarily requiring manufacturing capacity and organizational costs to increase at the same rate as revenue.


The recurring nature of single-use endoscopy is particularly attractive in this context. Once a hospital adopts Ambu's products, every additional procedure generates demand for another endoscope. As procedure volumes increase, Ambu can generate additional sales from existing customer relationships without having to acquire an entirely new customer for every device sold.


If sales volumes continue increasing, Ambu should also benefit from economies of scale. Higher production volumes can improve factory utilization, support more efficient purchasing of components, and reduce manufacturing costs per device. This could allow operating profits to grow faster than revenue and invested capital, supporting higher ROIC.


There are also reasons to remain cautious. Single-use endoscopy remains a relatively young market, and Ambu faces increasing competition from established medical technology companies. Hospitals are sensitive to purchasing costs, and reusable endoscopes remain economically attractive in many clinical settings. If adoption develops more slowly than expected or competition puts pressure on pricing, Ambu may struggle to generate the earnings growth needed to improve ROIC.


Furthermore, the company's expansion into gastrointestinal endoscopy represents a potentially significant opportunity but also requires continued investment in product development, clinical performance, and commercialization. The timing and profitability of these investments remain uncertain.


Overall, Ambu's ROIC history is less impressive than I would ideally like to see. The company generated attractive returns before embarking on an ambitious expansion strategy, but the subsequent increase in invested capital and pressure on profitability caused ROIC to remain below 10% for six consecutive years.


Nevertheless, the recovery since 2022 is encouraging. ROIC has improved from just 1,8% to 10,1%, suggesting that the strategic and operational changes introduced under Britt Meelby Jensen are beginning to produce results.


I believe Ambu has a reasonable opportunity to improve ROIC further as single-use endoscopy adoption increases, manufacturing efficiency improves, and existing investments generate additional revenue. However, I would not automatically expect a return to the levels achieved in 2017 and 2018, when the company operated with a smaller capital base and faced less competition.



The next number we will look into is equity. This is one of the most important indicators I use when evaluating a company's long-term financial development. I prefer to see equity increasing consistently over a 10-year period, ideally by more than 10% annually.


To put it simply, equity represents the part of a company that belongs to its shareholders after subtracting liabilities from assets. Growing equity over time can indicate that a company is strengthening its financial position and accumulating value for shareholders. However, it is also important to understand where the growth comes from, as equity can increase through retained earnings, new share issuances, and other changes to the balance sheet.


Ambu has increased equity every year throughout the past decade, from DKK 1,28 billion in 2017 to DKK 6,25 billion in 2026. This represents almost a fivefold increase, although growth has varied considerably. Equity increased by 47,2% in 2018, 66,6% in 2021, and 26,6% in 2023, while growth has been more modest recently, reaching 3,7% in 2024, 7,9% in 2025, and 3,6% in 2026.


One of the main reasons for this development is Ambu's consistent profitability. Even during the challenging years when operating margins and ROIC declined significantly, the company continued generating positive earnings. Retaining part of these earnings within the business has allowed Ambu to strengthen its equity position over time.


However, Ambu's equity growth has not been driven exclusively by profits. The company has also raised capital from shareholders to finance its expansion into single-use endoscopy. This helps explain why equity increased particularly strongly in certain years, especially in 2021, when it grew by 66,6%. New share issuances strengthen equity but do not necessarily create additional value for existing shareholders because they can result in dilution.


This is particularly relevant when comparing equity growth with ROIC. Ambu's equity increased substantially during a period when ROIC declined from 18,4% in 2017 to just 1,8% in 2022. The company was building a larger business and investing heavily in manufacturing capacity, product development, and international expansion, but the earnings generated from these investments did not initially increase at the same pace.


Since Britt Meelby Jensen became CEO in 2022, Ambu has placed greater emphasis on profitable growth, operational efficiency, and improving returns on its investments. This has supported a recovery in profitability, although equity growth has slowed considerably compared with the earlier expansion period.


In fiscal year 2026, Ambu's equity increased to DKK 6,25 billion, representing growth of 3,6%. The relatively modest increase was partly because Ambu spent DKK 450 million buying back its own shares. This reduced the company's equity, even though its profitability continued to improve.


Share repurchases are important when evaluating future equity growth because they reduce the company's equity even when profitability improves. If Ambu continues returning substantial amounts of capital through buybacks, equity may increase more slowly than earnings. This is not necessarily negative for shareholders, particularly if shares are repurchased at attractive valuations.


Looking ahead, there are good reasons to believe that Ambu can continue growing equity. The company has established a leading position in single-use endoscopy, benefits from recurring demand for disposable medical devices, and has already invested substantially in its global manufacturing and commercial infrastructure.


As adoption of single-use endoscopy increases, Ambu could generate additional revenue and earnings without requiring investments to increase at the same pace. Improving manufacturing efficiency and higher production volumes could also support stronger profitability, allowing the company to finance more of its future growth through internally generated earnings.


However, I would not expect Ambu to consistently repeat the extraordinary equity growth rates achieved in certain earlier years. Future growth will increasingly depend on operating profitability rather than large capital increases, while continued share repurchases, acquisitions, and investments could also affect the development.


Overall, I find Ambu's consistent equity growth encouraging, particularly given the operational challenges the company has experienced. However, the most important question is whether Ambu can generate attractive returns on its growing capital base. The recovery in ROIC to 10,1% in 2026 is encouraging, and if Ambu can combine continued equity growth with ROIC consistently above 10%, it would provide stronger evidence that the company's investments are creating lasting value for shareholders.



Finally, we will analyze the free cash flow. Free cash flow, in short, refers to the cash that a company generates after covering its operating expenses and capital expenditures. I use levered free cash flow margin because I believe that margins provide a better understanding of the numbers. Free cash flow yield refers to the amount of free cash flow per share that a company is expected to generate in relation to its market value per share.


Ambu's free cash flow has fluctuated considerably over the past decade, reflecting a period of significant investments, operational challenges, and subsequent improvements in profitability. However, the overall development has been encouraging, with free cash flow increasing from DKK 303 million in 2017 to a record DKK 861 million in fiscal year 2026. The levered free cash flow margin reached 13,3% in 2026, its highest level since 2019, indicating that Ambu is becoming more effective at converting revenue into cash.


One of the main reasons Ambu generates free cash flow is the recurring nature of its business. Hospitals continuously purchase its disposable endoscopes, anesthesia products, and patient monitoring equipment. Once a hospital adopts Ambu's single-use endoscopes, every additional procedure generates demand for another device. This provides a recurring source of revenue that can support cash generation as procedure volumes increase.


However, Ambu's business also requires substantial investments. The company manufactures its own medical devices and must invest in production facilities, equipment, research and development, and inventory. During its expansion into single-use endoscopy, Ambu invested heavily in building manufacturing capacity and developing products for additional clinical specialties. These investments required significant cash before the associated revenue and earnings had fully materialized.


This helps explain why free cash flow declined considerably after 2019. It fell from DKK 433 million in 2019 to DKK 151 million in 2020 and remained relatively low in 2021. The levered free cash flow margin declined from 15,4% in 2019 to just 3,8% in 2021, reflecting the combination of substantial investments and pressure on profitability.


The most challenging year was 2022, when free cash flow turned negative at DKK 43 million. Ambu was dealing with slower-than-expected growth in certain endoscopy markets, operational inefficiencies, and significant investments in its manufacturing and commercial organization. The company also increased inventory to protect against supply chain disruptions. These factors reduced the cash generated by the business while investment requirements remained elevated.


The recovery since 2022 has been substantial. Free cash flow increased to DKK 447 million in 2023 and DKK 725 million in 2024, supported by improving profitability, stronger commercial execution, and more disciplined operations under Britt Meelby Jensen. Higher sales volumes also helped Ambu utilize its manufacturing facilities more efficiently, allowing the company to generate more cash from investments that had already been made.


Free cash flow declined slightly to DKK 674 million in 2025, partly because Ambu increased inventory ahead of product launches and maintained additional stock to protect against supply chain uncertainties. However, the levered free cash flow margin remained healthy at 11,2%, suggesting that the underlying business continued generating substantial cash despite these temporary requirements.


In fiscal year 2026, free cash flow reached a new record of DKK 861 million, while the margin improved to 13,3%. This was supported by continued revenue growth, stronger operating cash generation, and improved efficiency across the business. Ambu's increasing scale has allowed it to spread costs across higher sales volumes, while disciplined cost management has helped the company convert more of its revenue into cash.


The improvement is particularly encouraging because Ambu has continued investing in future growth. The company has been expanding its manufacturing operations in Mexico and Malaysia, developing new generations of single-use endoscopes, and strengthening its digital capabilities. Generating record free cash flow while continuing these investments suggests that the underlying business has become financially stronger.


However, I would be careful about expecting another free cash flow record in fiscal year 2027. Ambu has indicated that capital expenditures will increase temporarily as the company prepares to launch four next-generation endoscopes over the coming years. These investments include additional manufacturing capabilities, automation, quality control equipment, and research and development.


Ambu expects to generate slightly less free cash flow in 2027 because it plans to invest more in developing and launching new endoscopes, as well as improving its manufacturing facilities. This is not necessarily negative, as these investments are intended to support future growth and profitability. Management expects cash generation to improve again in the following years.


Looking further ahead, management remains confident in its ability to improve cash generation. Under the ZOOM AHEAD strategy, Ambu targets annual organic revenue growth averaging 11% to 13% through fiscal year 2030 and an EBIT margin exceeding 20% by the end of that period. The company also targets cash conversion of at least 40% over the longer term.


If Ambu achieves these objectives, free cash flow could increase considerably. Higher sales of single-use endoscopes would generate additional recurring revenue, while improved manufacturing efficiency and a larger business could allow operating profits to grow faster than costs. However, the company will still need to invest in innovation and production capacity, meaning free cash flow is unlikely to increase every year.


Ambu primarily uses its cash generation to invest in future growth, maintain a strong financial position, and return capital to shareholders. Reinvestment includes developing new endoscopes, improving visualization technology, expanding manufacturing capacity, and strengthening its commercial organization. The company also uses capital for acquisitions that support its strategy, such as the purchase of TIMS Medical in 2026, which expanded Ambu's capabilities in medical video connectivity and documentation.


Returning cash to shareholders has also become an increasingly important priority. During fiscal year 2026, Ambu distributed approximately DKK 560 million through dividends and share buybacks, including DKK 450 million in repurchases. These were the company's first share buyback programs in eight years, reflecting its improved financial position.


For fiscal year 2027, Ambu has announced plans to return approximately DKK 551 million to shareholders through a proposed dividend of DKK 151 million and a DKK 400 million share buyback program.


Overall, I find Ambu's free cash flow development encouraging. The company has recovered from negative free cash flow in 2022 to a record DKK 861 million in 2026, while its levered free cash flow margin has improved significantly. This suggests that Ambu is beginning to benefit financially from the substantial investments made during its earlier expansion.


Although higher capital expenditures may temporarily reduce free cash flow in 2027, I believe Ambu has good opportunities to generate more cash over the longer term. The key will be whether continued growth in single-use endoscopy, improving manufacturing efficiency, and stronger profitability can outweigh the investments required to support future expansion. If Ambu succeeds, it should be able to combine higher free cash flow with continued investment in its business and increasing returns to shareholders.


The free cash flow yield suggests that while Ambu still trades at a premium valuation, the stock is currently more attractively valued than at any other point in the past decade. However, we will revisit the valuation later in the analysis.



Debt


Another important aspect to consider is debt. One way to judge whether a company’s debt is manageable is to see if it could repay it within three years using its earnings. In Ambu’s case, this is extremely straightforward because the company currently has just 0,05 years of earnings in long-term debt. Ambu has financed its growth primarily through its own cash generation and shareholder capital rather than relying heavily on borrowing. This puts the company in a very strong financial position and gives it considerable flexibility to invest in new products, expand its manufacturing capabilities, make acquisitions, and return capital to shareholders. Management has also emphasized the importance of maintaining a strong balance sheet, which should allow Ambu to pursue future growth opportunities without taking on excessive financial risk.


Support the Blog


I want to keep the blog free and accessible for everyone. If you enjoy the content and would like to support it, you can buy me a cup of coffee through PayPal. Every little bit helps and is truly appreciated!


Risks


Geopolitical and economic uncertainty is a risk for Ambu because the company operates globally, with manufacturing facilities in Malaysia, China, Mexico, and the United States, while selling its products across more than 60 markets. This exposes Ambu to trade disputes, tariffs, inflation, and political developments that can increase costs and disrupt its operations, even when demand for its medical devices remains strong.


Tariffs are particularly important because Ambu manufactures products in one country and sells them in another. When governments introduce import tariffs, the cost of supplying these products increases, potentially reducing profitability unless Ambu can raise prices or lower costs elsewhere. This is especially relevant to the United States, which is Ambu's largest market.


Ambu has already experienced the financial consequences of tariffs. Management explained that tariffs have affected operating expenses over the past two financial years and expects them to reduce profitability by approximately one percentage point in fiscal year 2027. This demonstrates that geopolitical developments can have a meaningful impact on Ambu's earnings, even when the underlying business continues growing.


Tariffs can also force Ambu to change where it manufactures its products. The company has been expanding its manufacturing facility in Mexico and transferring more production intended for American customers closer to the United States. However, relocating production creates additional costs and operational challenges. Employees must be trained, equipment must be installed and tested, and manufacturing processes must meet strict medical quality standards.


Furthermore, moving production to Mexico does not eliminate the geopolitical risk. Trade agreements and tariff policies can change, and Mexico itself could become subject to additional restrictions. This means Ambu could spend considerable resources adjusting its manufacturing operations only to face new trade barriers later.


Trade restrictions could also strengthen Ambu's competitors. If competing medical device manufacturers produce their products within the United States or benefit from more favorable trade arrangements, they may face lower costs than Ambu. This could allow competitors to offer more attractive prices or maintain higher profit margins. Ambu would then face the difficult choice of absorbing the additional costs or increasing its prices, potentially weakening its position against competing products.


Supply chain disruptions represent another important risk. Ambu depends on suppliers across different countries for components such as electronics, medical-grade plastics, and other materials used in its devices. Geopolitical tensions, trade restrictions, or transportation disruptions could make certain components more expensive or difficult to obtain.


This is particularly important because medical devices must meet strict quality and regulatory requirements. Ambu cannot necessarily replace a supplier immediately if a component becomes unavailable. Alternative components or suppliers may need to be tested and approved before they can be used in production. Consequently, disruptions involving even relatively small components could delay manufacturing and affect Ambu's ability to supply customers.


Inflation represents another potential challenge. Ambu depends on materials, components, labor, energy, and transportation to manufacture and distribute its products. Rising costs in these areas could reduce profitability, particularly if the company cannot pass the additional expenses on to customers through higher prices. Since single-use endoscopes are sold for individual procedures, even relatively small increases in manufacturing costs per device could become significant as sales volumes grow.


Regulatory requirements are a risk for Ambu because the company operates in the medical technology industry, where products must meet strict requirements for patient safety, quality, and performance. As Ambu develops, manufactures, and sells medical devices across more than 60 markets, it must comply with different laws and regulations in each region. Failure to meet these requirements could result in delayed product launches, fines, legal proceedings, or restrictions on selling its products.


One of the most important regulatory risks concerns the approval of new medical devices. Before Ambu can introduce a new endoscope or visualization system, it must demonstrate that the product meets the relevant safety and performance standards. This requires extensive testing, technical documentation, and regulatory reviews. In the United States, medical devices are regulated by the Food and Drug Administration (FDA), while products sold in the European Union must comply with the EU Medical Device Regulation (MDR).


This is particularly relevant because Ambu's growth strategy depends heavily on introducing new generations of single-use endoscopes and expanding into additional medical specialties. If a product fails to meet regulatory requirements or authorities request additional documentation, its launch could be delayed. Such delays could postpone expected revenue, increase development costs, and give competitors more time to introduce alternative products.


Regulatory requirements can also change while a product is being developed. For example, the European Union's Medical Device Regulation introduced stricter requirements for clinical evidence, documentation, and ongoing monitoring of medical devices. Changes like these can force Ambu to conduct additional testing, modify products, or obtain new certifications. This could increase costs and create uncertainty around product launches and the continued sale of existing devices.


Regulatory risk does not disappear once a medical device has been approved. Ambu must continuously monitor the safety and performance of its products and maintain consistent quality throughout manufacturing. If a defect is discovered or a product fails to meet regulatory standards, authorities could require corrective action, additional testing, or a product recall.


Product recalls could be particularly damaging because Ambu supplies medical devices used directly in patient care. A problem involving an endoscope could force hospitals to stop using the affected product while Ambu investigates and resolves the issue. Depending on the severity, this could lead to replacement costs, legal claims, lost revenue, and damage to relationships with hospitals.


Manufacturing quality represents another important part of the regulatory risk. Ambu operates production facilities in several countries and relies on external suppliers for components and materials. If a manufacturing facility or supplier fails to meet the required quality standards, Ambu could face regulatory inspections, production interruptions, or restrictions on distributing affected products. Expanding or relocating production can also require additional testing and documentation to ensure that manufacturing processes continue meeting regulatory requirements.


Ambu is also exposed to regulations concerning healthcare-related business practices. Medical device companies interact closely with hospitals, healthcare professionals, distributors, and public healthcare systems. These relationships are subject to rules intended to prevent bribery, corruption, and inappropriate financial incentives. Violations could result in investigations, fines, restrictions on participating in public tenders, or damage to Ambu's reputation.


Data protection is becoming increasingly relevant as Ambu expands its digital capabilities. Its visualization systems and medical video solutions may involve the handling or transfer of sensitive patient information. This creates obligations under data protection legislation, including the EU's General Data Protection Regulation (GDPR). As Ambu develops more advanced software and potentially introduces artificial intelligence into its products, additional requirements concerning cybersecurity, data protection, and software safety could increase costs or delay new product launches.


Healthcare cost pressures are a risk for Ambu because hospitals, governments, and healthcare systems are under constant pressure to reduce spending while treating more patients. As healthcare costs increase, hospitals must carefully consider which medical devices they purchase and whether new technologies justify their costs. This can lead to tougher price negotiations, delayed purchasing decisions, and slower adoption of new products, potentially affecting Ambu's revenue growth and profitability.


This risk is particularly relevant because hospitals are Ambu's primary customers, and many operate within budgets determined by governments, insurance providers, or healthcare organizations. Even when a medical device offers clinical benefits, purchasing decisions are often influenced by financial considerations. If hospitals face budget restrictions, they may prioritize essential equipment and existing treatments rather than introducing new technologies.


Ambu's Anesthesia & Patient Monitoring business is especially exposed to pricing pressure. This segment includes established products such as resuscitators, breathing circuits, and patient monitoring electrodes. Many of these products are available from several manufacturers, making it easier for hospitals to compare prices and negotiate with suppliers. Ambu has historically experienced modest pricing pressure in this business, but tighter healthcare budgets could make competition increasingly focused on price.


This creates a risk because hospitals and purchasing organizations may demand lower prices or more favorable contract terms. Large hospital groups can negotiate purchases across multiple facilities, giving them considerable bargaining power. If Ambu must reduce prices to retain customers or win contracts, profitability could decline even if sales volumes remain stable or increase.


The situation is different in Ambu's Endoscopy Solutions business, where pricing has historically been more stable. However, single-use endoscopes face an important challenge because hospitals must purchase a new device for every procedure. Unlike reusable endoscopes, which can be cleaned and used repeatedly, single-use devices create a recurring purchasing expense that hospitals must consider when evaluating their budgets.


Although reusable endoscopes require cleaning, maintenance, repairs, and specialized equipment, hospitals may already have invested heavily in these systems. As a result, the additional cost of purchasing a disposable endoscope for each procedure can appear unattractive, particularly when existing reusable equipment is still functioning. This could make hospitals reluctant to switch, even if single-use devices offer advantages in infection prevention and workflow efficiency.


The financial comparison also depends on how frequently hospitals perform procedures. Hospitals conducting large numbers of procedures may be able to spread the costs of reusable endoscopes and cleaning equipment across many patients, potentially making reusable devices more economical. Smaller hospitals or departments performing fewer procedures may face a different calculation. This means the financial case for single-use endoscopy can vary considerably between customers, potentially limiting adoption in certain settings.


Healthcare cost pressures could also slow Ambu's expansion into new medical specialties. The company is developing single-use endoscopes for areas where reusable devices remain widely established. Introducing these products requires convincing hospitals that the clinical and operational benefits justify changing their existing procedures. If hospitals become increasingly focused on reducing costs, they may postpone adoption or limit single-use devices to specific procedures rather than replacing reusable endoscopes more broadly.


Government healthcare policies and reimbursement systems represent another important risk. Reimbursement determines how hospitals and healthcare providers are paid for performing medical procedures. If reimbursement rates fail to keep pace with rising treatment costs, hospitals may face greater pressure to reduce spending on medical devices. Changes in reimbursement policies could also make certain procedures less financially attractive, indirectly affecting demand for Ambu's products.


The risk could become more significant during periods of government spending cuts or healthcare reform. Public healthcare systems may introduce stricter purchasing requirements, encourage centralized procurement, or negotiate lower prices with medical device suppliers. These developments could reduce Ambu's pricing flexibility and make it more difficult to achieve its long-term growth and profitability targets.


Reasons to invest


The shift to single-use endoscopes is a reason to invest in Ambu because the global endoscopy market is undergoing a structural transition from reusable to disposable medical devices. Ambu is the global market leader in single-use endoscopy, with a market share exceeding 60%, and is well positioned to benefit as hospitals increasingly adopt these solutions. Importantly, this transition is still in its early stages, creating opportunities for Ambu to grow for many years.


According to Ambu, only 3% to 4% of the global endoscopy market has transitioned to single-use solutions. The company estimates that the total market opportunity could reach approximately DKK 190 billion if all endoscopy procedures eventually used single-use devices. This is not a forecast of what the market will become, but it illustrates how much of the potential market remains served by reusable endoscopes.


The single-use endoscopy market is expected to grow by more than 20% annually between 2025 and 2030. According to Ambu, approximately 5% of this growth will come from an increasing number of endoscopy procedures, while more than 15% will come from hospitals switching from reusable to single-use devices. This distinction is important because Ambu does not need the overall number of medical procedures to increase dramatically. It can also grow by replacing reusable endoscopes in procedures that hospitals are already performing.


One of the main reasons hospitals are adopting single-use endoscopes is improved efficiency. Reusable endoscopes must be transported, cleaned, disinfected, inspected, and prepared between procedures. This requires specialized equipment, trained employees, and time. Single-use endoscopes arrive ready for use and can be discarded after a procedure, eliminating many of these steps.


This becomes increasingly important as healthcare systems face rising patient volumes and shortages of healthcare professionals. Hospitals need to treat more patients without increasing staffing at the same pace. According to figures highlighted by Ambu, eliminating cleaning and transportation between bronchoscopy procedures can reduce the time between procedures by 34%. The company has also highlighted evidence that using single-use cystoscopes can increase the number of procedures performed by approximately 50%.


The financial benefits can also encourage adoption. Although hospitals must purchase a new single-use endoscope for every procedure, reusable endoscopes involve additional expenses for cleaning, repairs, maintenance, and specialized equipment. When these costs are included, single-use devices can become economically attractive. Ambu has highlighted studies indicating that single-use bronchoscopes can reduce costs by approximately 13% compared with reusable alternatives, while single-use cystoscopes can offer savings of around 10%.


Another important advantage is infection prevention. Reusable endoscopes must be thoroughly cleaned and disinfected after every procedure, and failures in this process can create a risk of contamination between patients. Single-use endoscopes eliminate the need to reprocess the device, reducing the possibility of infections caused by inadequate cleaning. This is particularly relevant for procedures involving vulnerable patients, where preventing infections is especially important.


The transition toward outpatient care provides another opportunity. More medical procedures are being performed outside traditional hospitals, including outpatient clinics and specialized treatment centers. These facilities may not have the equipment, personnel, or space required to clean and maintain reusable endoscopes. Ambu's portable, ready-to-use solutions allow procedures to be performed without establishing an extensive cleaning infrastructure, potentially making single-use devices attractive in these settings.


The opportunity also differs considerably between medical specialties. According to Ambu, approximately 20% of respiratory endoscopy procedures currently use single-use devices, compared with around 10% in urology and just 2% to 4% in Ear-Nose-Throat (ENT). Gastroenterology (GI) remains below 1%, meaning reusable endoscopes still dominate the vast majority of procedures in these markets.


Gastroenterology is particularly interesting because it represents the largest potential market. Ambu estimates the global GI endoscopy opportunity at approximately DKK 120 billion, compared with DKK 35 billion in urology, DKK 20 billion in ENT, and DKK 15 billion in respiratory endoscopy. Even relatively modest adoption of single-use solutions in GI could therefore create a substantial market, although achieving widespread conversion will take time.


The company's existing market position could also help it capture a meaningful share of future growth. With more than 60% of the global single-use endoscopy market, Ambu has established relationships with hospitals, experience introducing disposable endoscopes, and a specialized sales organization. These capabilities are valuable because converting hospitals from reusable to single-use devices involves more than selling a product. It also requires demonstrating clinical performance, explaining the financial benefits, and helping healthcare professionals change established procedures.


The recurring nature of single-use endoscopy is another attractive characteristic. Unlike reusable endoscopes, which can be used repeatedly over several years, a single-use endoscope must be replaced after every procedure. Once a hospital adopts these devices, each additional procedure creates demand for another endoscope. As adoption increases and procedure volumes grow, Ambu can therefore benefit from recurring product sales rather than relying entirely on hospitals purchasing new equipment.


Ambu's broad product portfolio is a reason to invest in the company because it allows Ambu to serve hospitals across several medical specialties while offering more than individual medical devices. The company has built a comprehensive portfolio covering Respiratory, Urology, Ear-Nose-Throat (ENT), and Gastroenterology (GI), supported by visualization systems, accessories, software, and services. This gives Ambu opportunities to strengthen customer relationships, expand its presence within hospitals, and generate revenue from several parts of the same medical procedure.


One of the most attractive aspects of Ambu's portfolio is that its products serve different departments within the same hospital. Respiratory products are used in operating rooms and intensive care units, while urology products support examinations of the bladder and urinary tract. ENT products are used to examine the nose and throat, while GI products support examinations of the digestive system. This broad presence allows Ambu to build relationships with multiple medical departments rather than depending on a single clinical specialty.


Respiratory remains an important part of the portfolio. Ambu offers several generations of bronchoscopes through its aScope product family, alongside its SureSight video laryngoscopes. These products serve complementary purposes, as bronchoscopes allow clinicians to examine the airways, while video laryngoscopes help them see the airway when inserting a breathing tube. Offering both solutions allows Ambu to serve more of the equipment needs of healthcare professionals working with patients who require airway management.


This combination is already contributing to growth. In fiscal year 2026, Ambu's Respiratory business achieved organic revenue growth of 14,6%, supported by its existing bronchoscope portfolio and increasing demand for SureSight. Management highlighted that these products complement each other commercially, allowing Ambu to strengthen relationships with existing customers while reaching additional procedures.


Ambu's Urology portfolio provides another example of the benefits of offering several related products. The company supplies cystoscopes for examining the bladder and ureteroscopes for procedures involving the urinary tract, including the treatment of kidney stones. It also offers accessories that support these procedures. This allows Ambu to provide customers with more complete solutions while generating additional revenue from procedures already performed using its endoscopes.


The strength of Ambu's portfolio is also reflected in its performance across Urology, ENT, and GI. Together, these areas achieved organic revenue growth of 18,2% in fiscal year 2026. Management emphasized that growth was broad-based, with existing cystoscopes and rhinolaryngoscopes remaining important contributors. This demonstrates that Ambu is benefiting from demand across several established product categories rather than depending entirely on one successful product.


Another advantage is Ambu's ability to serve different customer needs and price levels. Hospitals vary considerably in their requirements, procedure volumes, and budgets. By maintaining several generations of products within its portfolio, Ambu can offer solutions suited to different clinical settings. This provides greater commercial flexibility, particularly in markets where customers are increasingly sensitive to pricing.


Beyond individual medical devices, Ambu has developed its position as a provider of complete endoscopy solutions. Its EndoIntelligence platform brings together visualization systems, software, and connectivity across Respiratory, Urology, ENT, and GI. This allows hospitals to use a common technology platform across different departments, potentially simplifying equipment management, employee training, and everyday clinical workflows.


The ability to connect medical equipment with hospital information systems is particularly valuable. During endoscopy procedures, clinicians capture images and videos that may need to be included in patients' medical records. Ambu's connected solutions can help transfer this information directly into hospital systems, reducing administrative work. Management has highlighted that these integrations can strengthen customer loyalty because the equipment becomes more closely connected to a hospital's established workflows.


This part of the portfolio became stronger with Ambu's acquisition of TIMS Medical in September 2026. TIMS Medical specializes in medical imaging, reporting, and documentation solutions that integrate with hospital IT systems. The company brought approximately 7.000 installations across US hospitals, providing Ambu with an established customer network and additional capabilities beyond its existing endoscopy equipment.


The acquisition is particularly attractive for Ambu's ENT business, where TIMS Medical already has a strong presence. Ambu can combine its existing ENT products with TIMS Medical's documentation and connectivity solutions, allowing it to offer hospitals a more complete package. The approximately 7.000 installations also provide opportunities to introduce Ambu's products to existing TIMS Medical customers. Over time, management sees opportunities to extend these capabilities into other medical specialties and potentially additional geographical markets.


A broader portfolio can also strengthen Ambu's moat through higher switching costs. When hospitals use Ambu's endoscopes, visualization systems, accessories, and documentation software together, these products become more integrated into everyday operations. Replacing Ambu may then involve changes to equipment, software connections, employee training, and established procedures. This can make customers less inclined to change suppliers, particularly when several departments depend on the same technology platform.


Ambu's Anesthesia & Patient Monitoring business adds further breadth to the company. This segment includes established products such as resuscitators, breathing circuits, and patient monitoring electrodes. Although Endoscopy Solutions accounts for approximately two-thirds of revenue and represents Ambu's main growth engine, Anesthesia & Patient Monitoring provides additional revenue from medical products used in everyday patient care. This reduces the company's dependence on any single medical specialty.


The combination of these businesses creates opportunities to increase revenue from existing customers rather than relying entirely on attracting new hospitals. A customer purchasing bronchoscopes may also need video laryngoscopes, accessories, or connected visualization systems, while a hospital using Ambu's cystoscopes could become a customer for additional urology products or documentation software. As more hospitals adopt several parts of Ambu's offering, the company can strengthen its customer relationships, increase the value of each relationship, and build a more deeply integrated position within healthcare systems.


Innovation is a reason to invest in Ambu because the company has a long history of developing medical devices that address the changing needs of healthcare professionals. Innovation has been central to Ambu's development for nearly 90 years, from the introduction of the Ambu Bag to its position in modern endoscopy. By continuously improving its products and expanding their clinical applications, Ambu can strengthen its moat, reach additional patients, and create new opportunities for revenue growth.


Ambu has demonstrated its ability to introduce new products across several medical specialties. Between fiscal years 2022 and 2026, the company launched 12 solutions and secured four expanded clinical indications across Respiratory, Urology, Ear-Nose-Throat , and Gastroenterology. This track record is important because it shows that Ambu's growth does not depend entirely on one product or a single development project.


The company's investment in research and development is another attractive characteristic. According to management, Ambu has the highest R&D spending within single-use endoscopy, allowing it to develop technologies across its portfolio. This investment supports the company's ambition to maintain its technological leadership while introducing products that address increasingly complex medical procedures. It also creates barriers for smaller competitors that may struggle to match Ambu's development resources.


One of the clearest examples of innovation contributing to growth is Ambu's Respiratory business. The company introduced its SureSight video laryngoscope portfolio, including the SureSight Mobile solution, which received regulatory clearances in the United States and the United Kingdom. These products complement Ambu's existing bronchoscopes and provide healthcare professionals with additional tools for managing patients' airways.


Another important aspect of Ambu's innovation strategy is expanding the number of patients who can be treated with its existing technology. Two of the company's smallest aScope 5 bronchoscopes have received regulatory clearance for pediatric use in the United States and Europe. This allows the products to be used for additional patient populations without requiring Ambu to establish an entirely new medical specialty. As the number of approved applications increases, Ambu's products can become relevant to more clinicians and procedures.


Innovation is also supporting Ambu's expansion within Urology. The company has introduced additional accessories, including a grasper for cystoscopy and a FANS access sheath for ureteroscopy. The latter supports procedures involving the urinary tract, including kidney stone treatment. These additions strengthen Ambu's offering by addressing more of the equipment needs associated with complex procedures, potentially increasing the value generated from each procedure.


In Gastroenterology, Ambu has expanded the clinical applications of its aScope Gastro and aScope Gastro Large products to include sigmoidoscopy, a procedure used to examine the lower part of the large intestine. This represents an important step because Ambu's initial GI portfolio focused on examinations of the upper digestive tract. By expanding into additional procedures, the company can gradually increase the number of clinical applications its products address.


Ambu's innovation efforts also extend beyond endoscopy. Within Anesthesia & Patient Monitoring, the company received FDA clearance and CE marking for Neuroline Cup CT/MR, a brain monitoring solution designed to remain attached to patients during CT and MRI examinations. This reduces the need to remove and reapply monitoring equipment when patients undergo imaging, demonstrating how product development can improve clinical workflows in Ambu's more established business.


Looking ahead, Ambu has outlined an ambitious product development pipeline. Over the next two financial years, management expects to introduce more than seven new solutions, including four next-generation endoscope platforms covering Respiratory, Urology, ENT, and GI. The first of these is expected within ENT, followed by introductions across the remaining specialties.


Management has emphasized that these products represent new generations of endoscopes rather than minor improvements to existing devices. The objective is to improve clinical performance, strengthen Ambu's position against competing products, and expand the range of procedures and patient populations the company can serve. If successful, these launches could support growth in existing markets while opening additional opportunities.


Another important area of innovation is Ambu's EndoIntelligence platform. The company is investing in software, connectivity, cybersecurity, and artificial intelligence to support clinicians before, during, and after procedures. Rather than focusing exclusively on the physical endoscope, Ambu is developing technology that can assist with clinical decision-making, image management, and documentation. The acquisition of TIMS Medical has further strengthened these capabilities through its expertise in medical imaging and integration with hospital information systems.


One important consideration is that new product launches do not necessarily generate substantial revenue immediately. Management has explained that hospitals typically introduce new devices gradually, initially testing them in a limited number of procedures before expanding their use. This means the financial benefits of innovation may develop over several years rather than appearing immediately after a product receives regulatory clearance. With several new solutions scheduled for introduction, Ambu could benefit from overlapping periods of adoption rather than depending on a single major launch.


Ambu's ability to maintain a consistent flow of new products is therefore an important part of the investment case. Its established R&D organization, history of successful launches, and pipeline of next-generation endoscopes provide opportunities to strengthen its moat and expand its addressable market. If Ambu continues developing products that offer meaningful benefits to healthcare professionals, innovation could remain an important driver of revenue growth and profitability for many years.


Unlock Exclusive Seeking Alpha Discounts – Level Up Your Investing With Zero Risk

If you’ve been thinking about improving your investing process, this is the easiest way to start. These offers are only available through my links, and the Premium plan even comes with a 100% risk-free 7-day trial. Try everything for a week, and if it’s not for you, just cancel. You lose nothing.


1) Seeking Alpha Premium — Try It Free for 7 Days

Access the tools I personally use every day:

• Earnings transcripts

• Stock screeners

• Deep-dive analysis

• Portfolio tracking

• Market news with context that actually matters


Special Price: $269/year (normally $299) + 7-day free trial (for new users only)


Try Premium Free for 7 Days → HERE


(Explore everything — cancel anytime during the trial and pay $0.)


2) Alpha Picks — Proven Stock Ideas

This stock-picking service has delivered +287% returns vs. the S&P 500’s +77% (July 2022–Nov 2025).Great for investors who want curated, long-term picks backed by data.


Special Price: $449/year (normally $499)


Get Alpha Picks → HERE


(Although Alpha Picks doesn’t offer a free trial, its historical outperformance means the subscription can often pay for itself quickly if results persist. For many investors, the potential return far outweighs the upfront cost).


3) Premium + Alpha Picks Bundle — Best Value

Get both services together and save $159.Perfect if you want both broad tools and high-conviction stock ideas.


Special Price: $639/year (normally $798)


Get the Bundle → HERE


(This bundle doesn’t include a free trial, but it gives you both services at a $159 discount. You get Premium’s in-depth research plus Alpha Picks’ high-performing recommendations, making it the most comprehensive option for serious investors.)


Valuation


Now it is time to calculate the share price. I perform three different calculations that I learned at a Phil Town seminar. If you want to make the calculations yourself for this or other stocks, you can do so through the tools page on my website, where you have access to all three calculators for free.


The first is called the Margin of Safety price, which is calculated based on earnings per share (EPS), estimated future EPS growth, and estimated future price-to-earnings ratio (P/E). The minimum acceptable rate of return is 15%. I chose to use an EPS of 2,42, which is from fiscal year 2026. I have selected a projected future EPS growth rate of 15%. Finbox expects EPS to grow by 19,7% a year in the next five years but 15% is the highest I use. Additionally, I have selected a projected future P/E ratio of 30, which is twice the growth rate. This decision is based on Ambu's historically higher price-to-earnings (P/E) ratio. Finally, our minimum acceptable rate of return has already been established at 15%. After performing the calculations, we determined the sticker price (also known as fair value or intrinsic value) to be DKK 72,60. We want to have a margin of safety of 50%, so we will divide it by 2. This means that we want to buy Ambu at a price of DKK 36,30 (or lower, obviously) if we use the Margin of Safety price.


The second calculation is known as the Ten Cap price. The rate of return that a company owner (or stockholder) receives on the purchase price of the company essentially represents its return on investment. The minimum annual return should be at least 10%, which I calculate as follows: The operating cash flow last year was 1.065, and capital expenditures were 204. I attempted to analyze their annual report to calculate the percentage of capital expenditures allocated to maintenance. I couldn't find it, but as a rule of thumb, you can expect that 70% of the capital expenditures will be allocated to maintenance purposes. This means that we will use 143 in our calculations. The tax provision was 198. We have 261 outstanding shares. Hence, the calculation will be as follows: (1.065 – 143 + 198) / 261 x 10 = DKK 42,91 in Ten Cap price.


The final calculation is called the Payback Time price. It is a calculation based on the free cash flow per share. With Ambu's Free Cash Flow Per Share at DKK 3,30 and a growth rate of 15%, if you want to recoup your investment in 8 years, the Payback Time price is DKK 52,09.


Conclusion


I believe Ambu is an intriguing company with a strong management team. The company has built its moat through its leadership in single-use endoscopy, established customer relationships, manufacturing scale, proprietary technology, and integration into hospital workflows. Ambu's ROIC has exceeded 10% in only four of the past ten years, declining from 18,4% in 2017 to just 1,8% in 2022 as heavy investments and profitability pressures weighed on returns. However, ROIC has since recovered to 10,1% in fiscal year 2026, reflecting stronger profitability and improved operational efficiency. Ambu's free cash flow has also improved significantly, recovering from negative DKK 43 million in 2022 to a record DKK 861 million in fiscal year 2026, with a levered free cash flow margin of 13,3%, its highest since 2019. Although increased investments are expected to temporarily reduce free cash flow in 2027, continued revenue growth and greater manufacturing efficiency could support stronger cash generation over the longer term.


Geopolitical and economic uncertainty is a risk for Ambu because its global manufacturing operations and supply chain expose the company to tariffs, trade restrictions, supply disruptions, and rising costs. Tariffs are particularly concerning, as management expects them to reduce the operating margin by approximately one percentage point in fiscal year 2027, while changes in trade policies could require further adjustments to its manufacturing operations. Regulatory requirements are another risk because Ambu must comply with strict medical device regulations across more than 60 markets, which can increase costs and delay product launches. Failure to meet these requirements could also result in product recalls, legal proceedings, and reputational damage. Healthcare cost pressures represent an additional challenge, as tighter hospital budgets can lead to tougher price negotiations, delayed purchasing decisions, and slower adoption of new medical devices. This is particularly relevant for single-use endoscopes, as hospitals must weigh the recurring cost of disposable devices against their existing reusable equipment, potentially limiting adoption despite their clinical and operational benefits.


The shift to single-use endoscopes is a reason to invest in Ambu because the company holds more than 60% of a market expected to grow by over 20% annually through 2030, while only 3% to 4% of global endoscopy procedures have transitioned to single-use devices. As hospitals increasingly adopt these solutions to improve efficiency, reduce costs, and prevent infections, Ambu could benefit from substantial long-term growth and recurring revenue. Ambu's broad product portfolio is another reason to invest because it allows the company to serve multiple medical specialties with a comprehensive offering of endoscopes, visualization systems, accessories, and software. This creates opportunities for cross-selling, while integrating its products into hospital workflows through platforms such as EndoIntelligence can strengthen customer relationships and increase switching costs. Innovation is also an important reason to invest, as Ambu's substantial R&D investments and proven track record of product development allow it to expand into new procedures and patient populations. With more than seven new solutions planned over the next two financial years, including four next-generation endoscope platforms, Ambu has opportunities to strengthen its market position and support future growth.


I believe there are many things to like about Ambu, and buying shares below the Payback Time price of DKK 52 could represent a good long-term investment.


Follow my investment journey


I hope you enjoyed this analysis. I regularly publish in depth company analyses on InvestSeekers and share updates on the companies I follow.


If you would like to see what I currently invest in, I publicly share my portfolio and any changes I make over time. You can also learn how to follow or copy my portfolio through the investment platform I use.



Stay updated


If you enjoy my company analyses, you can sign up for my free newsletter to receive my latest analyses, investment ideas, and other updates directly in your inbox. Subscribers may also receive selected content before it is published publicly on InvestSeekers. Simply scroll to the bottom of this page and sign up.


Watch on YouTube


If you prefer a faster and more visual way to understand a company, I also publish videos on YouTube covering Nordic companies that receive relatively little coverage in English. Each video provides an understandable overview of the business, financials, risks, reasons to invest, and valuation.



Follow me on X


I also share more frequent investment updates on X, including company news, new analyses, and changes I make to my portfolio.



A cause I support


If you found my analysis valuable and would like to support a good cause, I encourage you to consider making a small donation to ADEPAC. It is a charity I know firsthand, and I have seen the valuable work they do despite having very limited resources.


Even a small donation can make a difference.




 
 
 

Comments


Never Miss a Post. Subscribe Now!

Thanks for submitting!

© 2020 by Glenn Jørgensen.

bottom of page